Institution Directory

Clinical trials at Moffitt Cancer Center

Sites in Tampa, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

713

Shown on this page

Current sort

Live official records

Conditions: Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Intensity-modulated radiotherapy, Magnetic Resonance Guidance; Radiation · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Smoking Cessation, Cervical Cancer, High Grade Cervical Dysplasia
Interventions: Smoking Cessation treatment delivered by Tobacco Free Florida Quitline, Nicotine patch, Nicotine Lozenge, Motivation and Problem Solving (MAPS) intervention; Behavioral · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Rectal Adenocarcinoma
Interventions: Capecitabine, Radiation Therapy, FOLFOX regimen; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Incurable Disease
Interventions: Evolutionary Tumor Board (ETB); Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cutaneous Sarcoma
Interventions: Pembrolizumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Tampa, Florida • Columbus, Ohio • Houston, Texas

Conditions: Brain Metastases, Brain Lesion
Interventions: Hypofractionated Stereotactic Radiosurgery; Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Metastatic Uveal Melanoma
Interventions: Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions: Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy; Radiation · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation); Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2039
U.S. locations: 72
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: MSGV1-PSCA-8T28Z, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pancreatic Carcinoma, Pancreatic Neoplasm
Interventions: Biospecimen Collection, Distal Pancreatectomy, Lanreotide, Questionnaire Administration, Saline; Procedure · Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 118
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 93 more

Conditions: Cutaneous Squamous Cell Carcinoma
Interventions: Cemiplimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 40
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more

About this Moffitt Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Moffitt Cancer Center in Tampa, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Moffitt Cancer Center

Filter and sort this campus

Live official records

Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC

Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

Preop fSRS for Resectable Brain Metastases

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

About this Moffitt Cancer Center institution page